Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gury Doshi"'
Autor:
Bradford R Hirsch, John M Burke, Manish Agrawal, Ralph J Hauke, Thomas E Hutson, Gury Doshi, Mark T Fleming, Nicholas J Vogelzang
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 3, Iss 1, Pp 23-35 (2016)
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The
Externí odkaz:
https://doaj.org/article/d0df7e06ded845189cfe1511e28aaeab
Autor:
Mary K. Anderson, Michael Brodersen, Stuart Genschaw, Gury Doshi, Eileen Peng, Wayne Ormsby, Patty Davis, Melissa S. Dillmon, Howard Cohen, Issam Makhoul, Steven L D Amato, Bill Wimbiscus, Rajiv Panikkar, Michael J. Reff, Luis E. Raez, Ellen A. Ronnen, Erin B. Kennedy
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(6)
PURPOSE To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications. METHODS An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6166c01823dc75f6317ce829a674b1cf
https://pubmed.ncbi.nlm.nih.gov/31815576
https://pubmed.ncbi.nlm.nih.gov/31815576
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 8:103-111
The toxicities of cisplatin, that is, nephrotoxicity, neurotoxicity and emesis, provided the impetus for the development of more tolerable platinum analogs. Satraplatin is an investigational third-generation orally available lipophilic platinum, whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e2036bc385e549dfab8925f8116ab11
https://doi.org/10.1517/17425255.2012.636352
https://doi.org/10.1517/17425255.2012.636352
Autor:
Bradford R Hirsch, Thomas E. Hutson, Gury Doshi, Ralph J. Hauke, John M. Burke, Manish Agrawal, Nicholas J. Vogelzang, Mark D. Fleming
Publikováno v:
Journal of Kidney Cancer and VHL
Journal of Kidney Cancer and VHL, Vol 3, Iss 1, Pp 23-35 (2016)
Journal of Kidney Cancer and VHL, Vol 3, Iss 1, Pp 23-35 (2016)
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1cc29e6ff919fe0a5e8ff6706f52da5
https://pubmed.ncbi.nlm.nih.gov/28326277
https://pubmed.ncbi.nlm.nih.gov/28326277